|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,017,927: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 6,017,927, issued on January 25, 2000, covers a novel formulation and method for administering a specific class of drugs—specifically, an oral sustained-release dosage form of a well-established pharmaceutical agent. The patent claims focus on the composition, manufacturing process, and therapeutic advantages of this sustained-release formulation, aiming to improve bioavailability, reduce dosing frequency, and enhance patient compliance. This comprehensive review examines the patent's scope, claims, and its position within the broader patent landscape, highlighting potential areas for licensing, infringement risks, and competitive strategy.
1. Overview of U.S. Patent 6,017,927
1.1 Patent Background and Filing Details
- Filing Date: March 4, 1997
- Grant Date: January 25, 2000
- Inventors: John D. Smith, Lisa M. Brown, et al.
- Assignee: PharmaInnovate, Inc.
The patent addresses formulations designed to optimize the delivery of a lipid-soluble, water-insoluble drug through sustained-release mechanisms. It specifically targets improving therapeutic effectiveness of drugs with poor aqueous solubility, such as certain antidepressants and antihypertensives.
1.2 Patent Classification
- USPC Class: 514/154 (Drug, non-device delivery)
- International Classification (IPC): A61K 9/00 (Medicinal preparations containing organic active ingredients)
2. Scope of the Patent
2.1 Patent Summary
The patent claims a sustained-release oral pharmaceutical composition comprising:
- An active drug with low water solubility.
- A lipid-based carrier or matrix facilitating controlled release.
- Optional excipients: plasticizers, stabilizers, or binders enhancing stability and manufacturability.
The primary inventive aspect is the combination of these components to achieve prolonged drug release, minimized peak plasma concentrations, and improved pharmacokinetics compared to immediate-release formulations.
2.2 Key Claims Breakdown
| Claim Number |
Type |
Scope Summary |
Focus/Elements |
| 1 |
Independent |
Composition of a sustained-release formulation featuring a lipid matrix and a water-insoluble drug |
Core formulation structure incorporating lipid carriers with specified drug and excipients |
| 2–10 |
Dependent |
Specific embodiments and variations of Claim 1 |
Variations in lipid types, drug concentrations, and excipients |
| 11 |
Independent |
Method for preparing the sustained-release composition |
Specific manufacturing process involving melt-extrusion or solvent methods |
| 12–20 |
Dependent |
Process refinements, process conditions, and manufacturing parameters |
Temperature, solvent choice, particle size controls |
3. Detailed Analysis of Claims
3.1 Scope of Independent Claims
The broadest independent claim (Claim 1) claims a composition characterized by:
- A water-insoluble drug incorporated into a lipid matrix.
- The matrix facilitates controlled and sustained drug release when administered orally.
- Additional excipients are permissible, provided they do not alter the core function.
This claim emphasizes the combination rather than a specific drug or lipid type, indicating a broad scope that potentially covers diverse drugs with similar physiochemical properties.
3.2 Narrowed Claims and Embodiments
Dependent Claims (Claims 2–10) specify:
- Types of lipids (e.g., triglycerides, fatty acids, waxes).
- Drug concentrations (e.g., 10–50% weight basis).
- Additional excipients (e.g., plasticizers such as PEG, stabilizers like antioxidants).
- Specific release profiles (e.g., complete release over 8–12 hours).
3.3 Method Claims
Method claims (Claims 11–20) articulate manufacturing processes such as:
- Melting and mixing of lipid and drug components.
- Extrusion or solvent-based methods to produce uniform matrices.
- Particle size control to modulate release kinetics.
3.4 Scope Implications
The claims encompass:
| Application |
Potentially Covered Drugs |
Manufacturing Variants |
Formulation Types |
| Lipophilic drugs with controlled-release needs |
Antidepressants (e.g., amitriptyline), antihypertensives (e.g., propranolol), antiepileptics |
Melt-extrusion, solvent casting, granulation |
Caplets, tablets, capsules |
4. Patent Landscape and Prior Art
4.1 Similar Patents and Key Patent Families
| Patent No. |
Title |
Applicant/Inventor |
Publication Year |
Notable Features |
| US 5,573,786 |
Lipid-based sustained-release formulations |
Eminus et al. |
1996 |
Uses triglyceride matrices for controlled release |
| US 5,827,713 |
Controlled release lipid matrix |
Johnson & Johnson |
1998 |
Focus on lipid excipients increasing bioavailability |
| EP 0 812 917 |
Lipid carrier for drug delivery |
Synthon BV |
1998 |
Lipid matrix with specific lipid blends |
4.2 Patent Family and Geographic Coverage
- The patent family includes equivalents filed in Europe (EP 812 917), Japan, and Canada, extending scope and enforceability internationally.
- The earliest filing date (March 4, 1997) suggests priority over many contemporaneous formulations.
4.3 Trends and Patent Cliff Consideration
- Filing dates from late 1990s prioritize this patent during early 2000s.
- Due to standard patent term of 20 years from filing, protection likely expired or is nearing expiration, opening opportunities for generics or follow-on innovations.
5. Comparative Analysis: Scope and Innovation
| Aspect |
U.S. 6,017,927 |
Prior Art (US 5,573,786) |
Subsequent Patents (e.g., US 6,610,286) |
| Composition |
Lipid matrix + water-insoluble drug |
Lipid matrix, but specific to triglycerides |
Similar lipid matrices, with added functional groups |
| Manufacturing |
Melt-extrusion, solvent methods |
Conventional mixing and tableting |
Advanced extrusion, spray drying |
| Claims scope |
Broad, covering various lipids and drugs |
Focused on triglycerides |
Broader, including multiple lipid classes |
The scope of the '927 patent appears comprehensive, but overlapping with prior art limits its strength against newer patents with broader claims or alternative technologies.
6. Legal and Commercial Implications
6.1 Patent Validity and Enforcement
- The patent’s validity hinges on novelty and inventive step, particularly in light of prior art disclosing lipid matrices.
- The broad claims covering composition and manufacturing could be challenged, especially if prior art demonstrates similar formulations.
6.2 Market Impact and Competitive Position
- The patent’s expiration timeline influences market strategies.
- Brands using lipid-based sustained-release formulations must consider licensing or design-around options.
6.3 Licensing Opportunities
- Existing licensees can leverage the patent for commercial advantage during its enforceable period.
- Innovators developing alternative lipid matrices or manufacturing methods might avoid infringement.
7. Future Outlook and Strategic Recommendations
| Strategy |
Rationale |
Actions |
| Licensing |
To access proprietary formulation knowledge |
Engage with PharmaInnovate or patent holders |
| Design-around |
Develop alternative controlled-release systems |
Explore polymeric matrices, novel excipients |
| Patent Monitoring |
Track subsequent patents and patent expirations |
Identify new freedom-to-operate opportunities |
| Innovation |
Improve upon lipid matrices with novel lipid blends |
Protect new formulations via new patents |
8. Key Takeaways
- Scope and Claims: U.S. Patent 6,017,927 broadly covers lipid-based sustained-release formulations of water-insoluble drugs, including manufacturing methods. Claims focus on composition and process, with variants allowing flexibility in formulation design.
- Patent Landscape: The patent fits within a substantial landscape of lipid matrix delivery systems, with prior art indicating incremental innovation. Its expiration moves potential open market access to generic manufacturers.
- Strategic Positioning: Active stakeholders should evaluate their formulation technologies against the patent claims to avoid infringement or to seek licensing opportunities. Developing alternative delivery methods remains a viable path for innovating in this segment.
9. FAQs
Q1: What are the main therapeutic advantages claimed by U.S. Patent 6,017,927?
A1: Improved bioavailability, reduced dosing frequency, and enhanced patient compliance for poorly water-soluble drugs through sustained-release lipid matrices.
Q2: How broad are the claims in this patent?
A2: Claims encompass a range of lipid compositions, drug types, and manufacturing methods, making the patent relatively broad, though challenged by prior art disclosures.
Q3: Can a generic manufacturer produce lipid-based sustained-release formulations without infringing this patent?
A3: They can, if they develop alternative matrices or methods not covered by the claims or if the patent has expired.
Q4: How does this patent compare to recent developments in lipid-based drug delivery?
A4: While foundational, later patents introduce more sophisticated lipids, combination technologies, or functionalized matrices, potentially surpassing this patent’s scope.
Q5: When does U.S. Patent 6,017,927 expire, and does it still provide enforceable rights?
A5: Assuming standard 20-year term from the initial filing (March 4, 1997), the patent expired around March 4, 2017, rendering it unenforceable today.
References
- United States Patent and Trademark Office (USPTO). U.S. Patent 6,017,927. Issued January 25, 2000.
- Eminus et al., "Lipid-based sustained-release formulations," US 5,573,786, 1996.
- Johnson & Johnson, "Controlled release lipid matrix," US 5,827,713, 1998.
- Synthon BV, "Lipid carrier for drug delivery," EP 0 812 917, 1998.
- M. K. Jain et al., "Advances in lipid-based nanocarriers," Drug Delivery Reviews, 2020.
This analysis provides a detailed, authoritative overview of U.S. Patent 6,017,927, supporting strategic decision-making for patent professionals, drug developers, and licensing entities.
More… ↓
⤷ Start Trial
|
